AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was the recipient of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 6,805,914 shares, a decline of 15.4% from the November 15th total of 8,047,193 shares. Approximately 7.0% of the company’s shares are sold short. Based on an average daily trading volume, of 1,479,580 shares, the short-interest ratio is currently 4.6 days.

A number of brokerages have recently issued reports on AVEO. began coverage on AVEO Pharmaceuticals in a research note on Wednesday, November 15th. They issued a “buy” rating and a $5.00 price objective on the stock. B. Riley began coverage on AVEO Pharmaceuticals in a research note on Monday, November 13th. They issued a “buy” rating and a $5.00 price objective on the stock. Seaport Global Securities reissued a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Friday, October 6th. Piper Jaffray Companies boosted their price objective on AVEO Pharmaceuticals from $3.80 to $4.50 and gave the company an “overweight” rating in a research note on Monday, August 28th. Finally, Zacks Investment Research downgraded AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the stock. AVEO Pharmaceuticals presently has an average rating of “Buy” and an average price target of $4.05.

AVEO Pharmaceuticals (NASDAQ:AVEO) opened at $2.93 on Friday. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of -0.32. AVEO Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $4.24.

Several large investors have recently made changes to their positions in AVEO. RA Capital Management LLC acquired a new position in shares of AVEO Pharmaceuticals in the 2nd quarter valued at about $18,727,000. Vanguard Group Inc. lifted its stake in shares of AVEO Pharmaceuticals by 48.6% in the 2nd quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after purchasing an additional 1,162,232 shares during the period. EAM Investors LLC acquired a new position in shares of AVEO Pharmaceuticals in the 2nd quarter valued at about $1,979,000. Essex Investment Management Co. LLC acquired a new position in AVEO Pharmaceuticals during the 3rd quarter worth approximately $550,000. Finally, OxFORD Asset Management LLP acquired a new position in AVEO Pharmaceuticals during the 3rd quarter worth approximately $228,000. 50.95% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/aveo-pharmaceuticals-inc-aveo-short-interest-update/1764728.html.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.